VIDEO: Therapy binds human kallikrein 2 in prostate cancer
Click Here to Manage Email Alerts
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of JNJ-6520 in prostate cancer, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, examined results that looked at the efforts of JNJ-6420 to bind human kallikrein (hK) 2 in metastatic castration-resistant prostate cancer.
“It was the first reported therapy that binds to hK 2, which is a new target in prostate cancer. And additionally, it's one of the first studies to report outcomes using actinium-225, which is a highly active alpha omitting radioligand that holds a great deal of promise in prostate cancer,” Chehrazi-Raffle said.
Collapse
Read more about
Click Here to Manage Email Alerts